Background
Methods
Patients
LSM
Direct measurement of serum M2BPGi
Surrogate serum markers
Statistical analysis
Results
Baseline clinical characteristics of patients
Features | Cases (n = 680) | Healthy (n = 164) |
P value |
---|---|---|---|
Male/Female, n | 465/215 | 76/88 | |
Age (years) | 54.9 ± 11.0 | 56.8 ± 14.8 | 0.02 |
IFN therapy N (%) | 291 (42.8%) | 0 (0.00%) | |
Habitual alcohol intake N (%) | 275 (40.4%) | ||
Body mass index | 23.6 ± 3.1 | 24.0 ± 3.1 | 0.114 |
Platelet count (×109/l) | 166.7 ± 74.8 | 228.3 ± 45.1 | <0.001 |
AST (15–46 IU/l) | 49.2 ± 39.9 | 26.4 ± 10.2 | <0.001 |
ALT (0–40 IU/l) | 37.7 ± 43.8 | 23.7 ± 15.1 | 0.011 |
GGT (12–73 IU/l) | 63.7 ± 105.3 | 27.2 ± 27.7 | <0.001 |
AFP (0–6.2 IU/l) | 7.46 ± 33.9 | ||
HCV genotype N (%) | |||
1b | 126 (18.5%) | ||
2a | 94 (13.8%) | ||
1b/2a | 2 (0.3%) | ||
Unknown | 459 (67.4%) | ||
Fibrosis markers | |||
APRI | 1.06 ± 2.72 | 0.30 ± 0.13 | <0.001 |
FIB4 | 4.84 ± 12.05 | 1.33 ± 0.55 | <0.001 |
AST/ALT ratio | 2.62 ± 2.80 | 1.45 ± 1.43 | <0.001 |
GPR | 0.58 ± 1.21 | 0.12 ± 0.12 | <0.001 |
M2BPGi | 1.57 ± 2.28 | 0.38 ± 0.23 | <0.001 |
Fibrosis stage (0 ~ 1/2 ~ 3/4) | 437/175/68 | 155/9/0 |
Correlation between M2BPGi and LSM in patients with HCV infection
Variables associated with LSM obtained by Fibro Scan®
Characteristic | Correlation analysis | liner regression analysis | ||
---|---|---|---|---|
rho |
P value | Effect size |
P value | |
Age | 0.188 | <0.001 | 0.015 | 0.606 |
Gender | −0.099 | 0.01 | −0.026 | 0.404 |
BMI | 0.038 | 0.318 | - | - |
Laboratory findings | ||||
Platelet count | −0.386 | <0.001 | −0.07 | 0.02 |
Total protein | 0.194 | <0.001 | −0.08 | 0.032 |
Albumin | −0.18 | <0.001 | −0.071 | 0.073 |
ALT | 0.403 | <0.001 | 0.017 | 0.732 |
AST | 0.499 | <0.001 | 0.008 | 0.893 |
ALP | 0.309 | <0.001 | 0.116 | 0.001 |
GGT | 0.432 | <0.001 | 0.13 | <0.001 |
Total Billirubin | 0.274 | <0.001 | 0.111 | 0.001 |
HA | 0.338 | <0.001 | 0.137 | <0.001 |
LN | 0.234 | <0.001 | 0.03 | 0.38 |
CIV | 0.34 | <0.001 | 0.099 | 0.003 |
AFP | 0.379 | <0.001 | 0.069 | 0.033 |
Fibrosis markers | ||||
FIB-4 indext | 0.412 | <0.001 | - | - |
APRI | 0.536 | <0.001 | - | - |
AST/ALT ratio | −0.141 | <0.001 | - | - |
GPR | 0.487 | <0.001 | - | - |
M2BPGi | 0.504 | <0.001 | 0.275 | <0.001 |
Comparison of AUCs and cut-off values for fibrosis markers
Fibrosis stage | Cutoff | AUC | Sensitivity | Specificity |
P value | |
---|---|---|---|---|---|---|
≥F2 | M2BPGi | 0.945 | 0.774 (0.736, 0.812) | 0.745 | 0.694 | Reference |
APRI | 0.635 | 0.787 (0.750, 0.824) | 0.708 | 0.799 | >0.05 | |
FIB4 | 3.145 | 0.702 (0.661, 0.743) | 0.650 | 0.686 | <0.001 | |
GPR | 0.221 | 0.764 (0.726, 0.801) | 0.704 | 0.716 | >0.05 | |
≥F4 | M2BPGi | 1.355 | 0.892 (0.851, 0.933) | 0.868 | 0.786 | Reference |
(Cirrhosis) | APRI | 0.885 | 0.873 (0.835, 0.910) | 0.838 | 0.783 | >0.05 |
FIB4 | 4.395 | 0.818 (0.768, 0.868) | 0.750 | 0.775 | <0.05 | |
GPR | 0.291 | 0.851 (0.808, 0.894) | 0.882 | 0.691 | >0.05 |